These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25089829)

  • 1. Is malignant nodule topography an additional risk factor for metastatic disease in low-risk differentiated thyroid cancer?
    Campennì A; Giovanella L; Siracusa M; Stipo ME; Alibrandi A; Cucinotta M; Ruggeri RM; Baldari S
    Thyroid; 2014 Nov; 24(11):1607-11. PubMed ID: 25089829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
    Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
    Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
    Sabra MM; Grewal RK; Tala H; Larson SM; Tuttle RM
    Thyroid; 2012 Sep; 22(9):877-83. PubMed ID: 22827641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isthmus topography is a risk factor for persistent disease in patients with differentiated thyroid cancer.
    Campennì A; Ruggeri RM; Siracusa M; Giacoppo G; La Torre F; Saccomanno A; Alibrandi A; Dionigi G; Tuccari G; Baldari S; Giovanella L
    Eur J Endocrinol; 2021 Aug; 185(3):397-404. PubMed ID: 34232125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation.
    Tuttle RM; Fleisher M; Francis GL; Robbins RJ
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1737-42. PubMed ID: 11932308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
    Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative TSH level and risk of thyroid cancer in patients with nodular thyroid disease: nodule size contribution.
    Zafón C; Obiols G; Mesa J
    Endocrinol Nutr; 2015 Jan; 62(1):24-8. PubMed ID: 25066642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgeon-performed ultrasound can predict differentiated thyroid cancer in patients with solitary thyroid nodules.
    Jabiev AA; Ikeda MH; Reis IM; Solorzano CC; Lew JI
    Ann Surg Oncol; 2009 Nov; 16(11):3140-5. PubMed ID: 19655201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome.
    Haq M; Harmer C
    Clin Endocrinol (Oxf); 2005 Jul; 63(1):87-93. PubMed ID: 15963067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer.
    Kovatcheva RD; Hadjieva TD; Kirilov GG; Lozanov BS
    Nucl Med Rev Cent East Eur; 2004; 7(1):13-9. PubMed ID: 15318305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment for microcarcinoma of the thyroid--clinical experience.
    Küçük NO; Tari P; Tokmak E; Aras G
    Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Tumor Size on Risk of Metastatic Disease and Survival for Thyroid Cancer: Implications for Biopsy Guidelines.
    Nguyen XV; Roy Choudhury K; Tessler FN; Hoang JK
    Thyroid; 2018 Mar; 28(3):295-300. PubMed ID: 29373949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid nodules and differentiated thyroid cancer.
    Bauer AJ
    Endocr Dev; 2014; 26():183-201. PubMed ID: 25231453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
    Vrachimis A; Schober O; Riemann B
    Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
    Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
    J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Factors for Early and Long-Term Remission in Pediatric Differentiated Thyroid Carcinoma: The Role of Sex, Age, Clinical Presentation, and the Newly Proposed American Thyroid Association Risk Stratification System.
    Pires BP; Alves PA; Bordallo MA; Bulzico DA; Lopes FP; Farias T; Dias F; Lima RA; Santos Gisler IC; Coeli CM; Carvalhaes de Oliveira RV; Corbo R; Vaisman M; Vaisman F
    Thyroid; 2016 Oct; 26(10):1480-1487. PubMed ID: 27540892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
    Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.